The Michael J. Fox Foundation Annual Report 2016 – Frameworks for Progress

Rappahannock Area YMCA Raymond James Canada Red Trust, Inc. Patricia Jehle and James Reidy Claudia and Carlos Revilla Robert Renzoni Vineyards Inc. Rebecca and Bryan Roberts Carolyn Robinson John Robinson Sandy and Mark Robinson Roddenberry Foundation Ray Romano Rob Rosania The Frances & David Rose Foundation Robert Rosen Cynthia and Peter Rosenwald Emerging Therapeutic Targets Georgina and Alan Rothenberg Several novel drug targets have been getting a lot of attention lately in Parkinson’s disease research — and for good reason. The Rothschild Foundation RPM Mortgage Inc. RTP Technology The Rubler Family Janice Rudbart Leah and Robert Rukeyser Julie and Gary Salomon David Samson Lee Savage Kenneth Schaner — C-Abl, a protein, has shown early promise as a potential disease-modifying therapy, and The Michael J. Fox Foundation (MJFF) funded research in this area as early as 2007. While much work remains to understand c-Abl’s role in PD progression, there is increasing activity to unlock key questions about its potential. The Foundation recently provided Georgia-based biotech Inhibikase with a grant to explore the development of advanced c-Abl inhibitors that show promise in pre-clinical models in terms of safety profile and brain penetrance versus other drugs in their class. Lorraine Schapiro Harry and Lila Schiffman Caren and William Schneider Diane Schroeder The Schwab Family Joanne Schwandt Meryl and Jeff Schwartz Leo A. Schwarz and Beverly Rupe Schwarz The Edward I. Seagraves Fund The Setton Foundation Oscar Shamamian Jeffrey Sharp The Short Family Elsa and Stanley Sidel Simplus Management Corporation Linda and Bob Sims Doenda and Donald Smith — An MJFF co-funded study with Gladstone Institute found that the single protein Nrf2 is key to fighting other faulty proteins that cause damage to neurons and kills brain cells. It also seems to interact with key PD drug targets LRRK2 and alpha-synuclein, ramping up scientific interest in its actions in body cells. Steven Finkbeiner, MD, PhD, senior author of the study, said that Nrf2 is “the most protective thing we’ve ever found.” Maria and Andrew Smith Suzanne and Peter Smith St. Clairsville Elementary School Mr. and Mrs. Erwin P. Staller The Stephen Colbert Americone Dream Fund Margaret P. Stevenson Foundation Tracy Storer Carol and Jim Storm Kate Strauchon James Stuart III Family Foundation Lisa and Scott Stuart Kellie Sumberac Nancy Sun The Geraldine and Gabriel Sunshine Fund Richard Swanson Charles F. Talbot Carol and Kink Terry James Todd Patricia and Michael Turnbull Richard Tauber The H.E. Thompson Foundation Sam Tradelius Gail Ullman Kelly Taylor Ramona and Charles Thompson Kent M. Thornbrugh Karin and Kenneth Travis Ultimate Software Group Inc. Craig Tedmon Robert Terhune Stephanie and Tom Thornburg Tree House Brewing Company / Nathan Lanier Alison and Bob Wachstein Voith Industrial Services Inc. 2016 Annual Report 17

The Michael J. Fox Foundation Annual Report 2016 – Frameworks for Progress | Page 19